Lv1
80 积分 2023-01-29 加入
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
6个月前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
7个月前
已完结
Toxicities From Antibody-Drug Conjugates
7个月前
已完结
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC
7个月前
已完结
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses
7个月前
已完结
TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity
8个月前
已完结
Lung cancer oncogene-directed therapy, fertility and pregnancy
10个月前
已关闭
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
10个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1年前
已完结
The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance
1年前
已完结
皖公网安备34019202002308
